Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.58 |
| ▸ | PIM1 | P11309 | 3/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952428 | 0.78 | CYP2A6 (0.70) | CYP2A6PIM1PIM3IMPDH2PIM2 | |
| SCHEMBL29935968 | 0.77 | CYP2A6 (0.64) | CYP2A6PIM1PIM3IMPDH2PIM2 | |
| SCHEMBL1092485 | 0.77 | CYP2A6 (0.64) | CYP2A6PIM1PIM3IMPDH2PIM2 | |
| SCHEMBL248842 | 0.75 | CYP2A6 (0.66) | CYP2A6PIM1PIM3IMPDH2PIM2 | |
| SCHEMBL29408411 | 0.75 | CYP2A6 (0.66) | CYP2A6PIM1PIM3IMPDH2PIM2 | |
| SCHEMBL27414727 | 0.75 | CTNNB1 (0.46) | CYP2A6PIM1PIM3CTNNB1WNT3A | |
| SCHEMBL644301 | 0.74 | CYP2A6 (1.00) | CYP2A6PIM1PIM3IMPDH2PIM2 | |
| SCHEMBL1337252 | 0.74 | CYP2A6 (0.64) | CYP2A6PIM1PIM3IMPDH2PIM2 | |
| SCHEMBL29954276 | 0.74 | CYP2A6 (0.64) | CYP2A6IMPDH2HTR1DHTR1BERN1 | |
| SCHEMBL6863442 | 0.74 | CYP2A6 (0.64) | CYP2A6PIM1PIM3IMPDH2PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596089-B1 | ANTIBACTERIAL COMPOUNDS | UNIV NOTTINGHAM (GB) | 2023-12-06 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11192888-B2 | Antibacterial compounds | THE UNIVERSITY OF NOTTINGHAM (GB) | 2021-12-07 | — | — | US | disclosed |
| US-11192888-B2 | Antibacterial compounds | THE UNIVERSITY OF NOTTINGHAM (GB) | 2021-12-07 | — | — | US | disclosed |
| US-20200199118-A1 | ANTIBACTERIAL COMPOUNDS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-06-25 | — | — | US | disclosed |
| US-20200199118-A1 | ANTIBACTERIAL COMPOUNDS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-06-25 | — | — | US | disclosed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| CN-101778850-A | Heteroaryl amide analogs | LUNDBECK & CO AS H | 2010-07-14 | — | — | CN | disclosed |
| EP-2185560-A1 | HETEROARYL AMIDE ANALOGUES | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009023623-A1 | HETEROARYL AMIDE ANALOGUES | H, LUNDBECK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023623-A1 | HETEROARYL AMIDE ANALOGUES | H, LUNDBECK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192888-B2 | Antibacterial compounds | CFTR, CLPP, MRPL21 | CYP2A6 2010/4885PIM1 636/4885PIM3 1118/4885 |
| US-20200199118-A1 | ANTIBACTERIAL COMPOUNDS | CFTR, CLPP, MRPL21 | CYP2A6 2010/4885PIM1 636/4885PIM3 1118/4885 |
| US-20120190680-A1 | Heteroaryl Amide Analogues | P2RX3, P2RX2, ADORA2A | CYP2A6 727/4885PIM1 4700/4885PIM3 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.